electroCore vs Iridex
ECOR and IRIX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ECOR and IRIX compare
electroCore is the larger company, worth 3.9 times as much as Iridex ($47.3M against $12.1M).
electroCore grew revenue faster over the last twelve months (27.3% versus 3.7% for Iridex).
Iridex keeps more of each dollar of sales as profit, with a net margin of −6.9% compared with −33.5% at electroCore.
Iridex scores higher on the StockData Score (8 against 7 for electroCore), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ECOR | IRIX |
|---|---|---|
| Size and price | ||
| Market cap | $47.3M | $12.1M |
| Share price | $5.25 | $0.690 |
| Change, 1 year | −13.4% | −27.7% |
| Change, 5 years | −53.8% | −91.0% |
| Beta (5Y) | 1.09 | 0.93 |
| Employees | 83 | 93 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 1 | 1 |
| Growth score | 4 (better) | 0 |
| Performance score | 1 | 2 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.2× | 0.2× (better) |
| P/B | – | 3.3× |
| FCF yield | −23.0% | −16.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 27.3% (better) | 3.7% |
| Revenue growth, 5Y average | 55.7% (better) | 7.7% |
| Profitability | ||
| Gross margin | 87.7% (better) | 35.9% |
| Operating margin | −33.1% | −5.4% (better) |
| Net margin | −33.5% | −6.9% (better) |
| FCF margin | −28.7% | −3.9% (better) |
| Return on equity | – | −73.1% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −960.7× | – |
| Current ratio | 1.34 | 1.82 (better) |
| Altman Z-score | −14.80 | −2.50 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 11.4% | 12.4% |
| Held by insiders | 16.6% | 76.1% |
| Insider net buying, 12 months | −$721K | $536K (better) |
| Short interest, % of float | 4.8% | 0.94% |
Go deeper
- ECOR stock overview
- ECOR income statement
- ECOR valuation and score
- IRIX stock overview
- IRIX income statement
- IRIX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.